Page 14 - Shauna Dillon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ObsEva SA: ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update

-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the

United statesShauna dillonBrian ocallaghanYuyuan bioscience technologyEuropean commissionDrug administrationSwiss exchangeExchange commissionManagement incSyneos healthEuropean medicines agencyOxford financeCommittee for medicinal products human useOffice contactBriano callaghanPrescription drug user fee act

ObsEva SA: ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

- Partnership leverages Theramex's leading women's health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside

United statesShauna dillonBrian ocallaghanRobert stewartExchange commissionSyneos healthKissei pharmaceutical co ltdSwiss exchangeUnited states foodDrug administrationforNew drug applicationBriano callaghanChief executive officerMiddle eastNasdaq global select marketPrivate securities litigation reform act

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

Investegate announcements from ObsEva SA, ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

United statesShauna dillonBrian ocallaghanRobert stewartSyneos healthExchange commissionKissei pharmaceutical co ltdDrug administrationSwiss exchangeObseva entersLicensing agreementUnited states foodNew drug applicationBriano callaghanChief executive officerMiddle east

ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesShauna dillonExchange commissionKissei pharmaceutical co ltdEuropean medicines agencyDrug administrationSwiss exchangeNew drug applicationUnited states foodNasdaq global select marketPrivate securities litigation reform actRisk factorsAnnual report

ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesShauna dillonExchange commissionKissei pharmaceutical co ltdEuropean medicines agencyDrug administrationSwiss exchangeNew drug applicationUnited states foodNasdaq global select marketPrivate securities litigation reform actRisk factorsAnnual reportObseva saUterine fibroidsGlobe newswire